BioSpace News Archive

NextCure, Inc. announced the presentation of biomarker data and updated clinical results from the Phase 1 portion of its ongoing Phase 1/2 monotherapy trial with NC318 at the 2020 Virtual American Society of Clinical Oncology Annual Meeting.

KEAPSAKE is a planned Phase 2 randomized trial exploring telaglenastat with standard of care in first-line treatment of patients with lung cancer with KEAP1/NRF2 mutations

Meridian Bioscience, Inc. announced that Jack Kenny, Chief Executive Officer, and Bryan Baldasare, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the 40th Annual William Blair Growth Stock Conference on Tuesday, June 9, 2020 at 8:40 AM CT.

BeiGene, Ltd. announced results from a Phase 3 clinical trial evaluating its anti-PD-1 antibody tislelizumab in combination with standard chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer, presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program.

As states begin to re-open, 40 percent of Americans still view going to the hospital as a risky behavior – even more than going to the hair salon, a concert or the beach, according to a new national survey released by the Society for Cardiovascular Angiography & Intervention.

Dr. Steven Quay, MD, PhD, physician-scientist and CEO of Atossa Therapeutics, Inc. announced that he and Dr. Martin Lee, PhD, Adjunct Professor of Statistics, UCLA Fielding School of Public Health, UCLA, Los Angeles, CA have published a manuscript entitled, “SARS-CoV-2 was spreading in the United States in late December 2019 and may have killed over 440 patients in California and 980 nationwide by mid-January.” The manuscript is available here: SARS in the US in Dec 2019.

Additional follow-up in Phase 3 ASPEN trial continued to show clinically meaningful safety and tolerability advantages for zanubrutinib compared to ibrutinib and demonstrated favorable CR/VGPR rate

Ipsen announced that its Board of Directors has appointed David Loew as its new Chief Executive Officer and as Board member.

The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian cancer

According to the report, the global urology imaging equipment market was valued at US$ 1.3 Bn in 2018 and is projected to expand at a CAGR of 4% from 2019 to 2027. The urology imaging equipment includes endovision systems, x-ray/fluoroscopy imaging systems, and ultrasound systems.